改造型 arrestin1 在三种遗传背景不同的小鼠视网膜病变模型中延缓退变
A modified Arrestin1 Slows Retinal Degeneration Across Genetically Distinct Mouse Models of Inherited Retinal Disease

bioRxiv 预印本报告,改造型 arrestin1(ArrGG)在 rd10、GC1KO 和 rd6 三种遗传背景不同的小鼠视网膜疾病模型中均与视网膜功能保留和结构退变减慢相关。转录组分析未发现 ArrGG 处理后有广泛、可重复的转录变化,支持其通过调节光感受器代谢而非转录重塑发挥作用。研究为动物实验,仅基于摘要,未给出样本量与效应量。
原文摘要
出版方登记 · CrossrefInherited retinal diseases (IRDs) are a genetically heterogeneous group of disorders caused by mutations in more than 340 genes, limiting the applicability of gene-targeted therapies and creating the need for broader treatment strategies. Photoreceptor dysfunction is a hallmark of IRDs and often results in disrupted retinal metabolic homeostasis, as photoreceptors have exceptionally high metabolic demands and provide metabolic resources to surrounding retinal cells. Consequently, enhancing retinal metabolism has emerged as a promising gene-agnostic strategy for treating IRDs. We previously developed a modified arrestin1 (ArrGG) that relieves arrestin1-mediated inhibition of the glycolytic enzyme enolase1, thereby increasing glycolytic output and slowing retinal degeneration in the RhoP23H/+ mouse model. Here, we investigated the therapeutic potential of ArrGG as a gene-agnostic approach targeting endogenous metabolic enzyme activity across genetically distinct models of IRD. Using two complementary photoreceptor-enriched transcriptomic analyses, we found no widespread, reproducible transcriptional changes following ArrGG treatment. These findings support our hypothesis that ArrGG modulates photoreceptor metabolism without inducing substantial transcriptional remodeling. The therapeutic efficacy of ArrGG was evaluated in three IRD mouse models representing rapid rod degeneration (rd10), cone degeneration (GC1KO), and RPE-associated retinal degeneration (rd6). ArrGG treatment was associated with preserved retinal function and slowed structural degeneration across all three models. Together, these findings support the potential of modulating endogenous metabolic enzyme activity to preserve photoreceptors across genetically distinct IRD models. This work suggests that ArrGG could be a promising gene-agnostic metabolic therapy for slowing retinal degeneration and preserving visual function in inherited retinal diseases.
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
来源:bioRxiv 神经科学 · biorxiv.org